

**VIVALIS ANNOUNCES A NEW EB66<sup>®</sup> CELL LINE RESEARCH LICENSE AGREEMENT WITH A MAJOR ANIMAL HEALTH COMPANY**

**Nantes & Lyon (France) – 22 December 2011** – VIVALIS (NYSE Euronext: VLS) announced today that it has signed a research license agreement with an undisclosed major animal health vaccine company granting them the rights to evaluate the EB66<sup>®</sup> cell line for the production of several animal health vaccine candidates.

Franck Grimaud, CEO, and Majid Mehtali, CSO, co-managers of VIVALIS jointly stated, *“This new agreement demonstrates that the EB66<sup>®</sup> cell line is a dominant standard for the production of viral vaccines. With this new agreement, the sixth signed this year which includes three commercial licenses, we are very pleased to achieve our yearly objective as we have in every previous year since the company’s IPO in 2007.”*

Terms of the agreement were not disclosed.

\*\*\*\*\*

**Next Financial Press Release**

January 24, 2012, after NYSE Euronext market closing: 2011 fourth-quarter sales

## **About VIVALIS (www.vivalis.com)**

VIVALIS (NYSE- Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of unmet medical needs. VIVALIS' expertise and intellectual property are leveraged in three main areas:

### 1. EB66<sup>®</sup> Cell Line

VIVALIS offers research and commercial licenses for its EB66<sup>®</sup> cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of therapeutic and prophylactic viral vaccines, virosomes, VLP's, and recombinant proteins (with a focus on monoclonal antibodies having enhanced cytotoxic activity). EB66<sup>®</sup> cell line based vaccines are currently in clinical trials in USA and in Japan. Through these programs VIVALIS receives upfront, clinical stage milestone payments along with royalties on licensees' net sales.

### 2. VIVA|Screen<sup>™</sup> Human Antibody Discovery Platform

Customized solutions for the discovery, development, and production of fully human monoclonal antibodies are now offered by VIVALIS. Through these programs VIVALIS receives upfront, clinical stage milestone payments along with royalties on licensees' net sales.

### 3. 3D-Screen<sup>™</sup> Drug Discovery Platform

VIVALIS performs discovery and development, up to pre-clinical evaluation, of original small chemical molecules identified with its proprietary platform, 3D-Screen<sup>™</sup>. This unique screening platform is designed to identify original molecules that alter the three-dimensional structure of a target protein, thus modulating its biological function through an innovative mode of action. VIVALIS is building a portfolio of proprietary new chemical entities for the treatment of hepatitis-C virus infection. VIVALIS also proposes, on a fee for service basis, to develop ready to use customized 3D-Screen<sup>™</sup> HTS assays directed against client's target protein of interest.

Based in Nantes & Lyon (France) and in Toyama (Japan) VIVALIS was founded in 1999 by the Grimaud Group (ca. 1,500 employees), a worldwide leader in animal genetic selection. VIVALIS has established more than 30 partnerships and licenses with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Transgene, Pfizer Animal Health, Kaketsuken, Kitasato Daiichi Sankyo Vaccine, Merial, Merck Animal Health, SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES and LYON BIPOLE bioclusters and a member of the Japanese OKURIKU INNOVATION CLUSTER FOR HEALTH SCIENCE in Toyama.

## VIVALIS

Listed on Euronext Paris – Compartment B of NYSE Euronext

Reuters: VLS.PA – Bloomberg: VLS FP

Included in NYSE Euronext's SBF 250, CAC Small 90 and Next Biotech indexes



*This document contains forward-looking statements and comments on the company's objectives and strategies. No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including the risk factors described in the company's registration document (document de référence), changes in economic conditions, the financial markets or the markets in which the company operates.*

## **Contacts**

### **VIVALIS**

Franck Grimaud, CEO

Email: [investors@vivalis.com](mailto:investors@vivalis.com)

### **NewCap**

Communication financière

Axelle Vuillermet / Pierre Laurent

Tél.: +33 (0) 1 44 71 94 91

Email : [vivalis@newcap.fr](mailto:vivalis@newcap.fr)